Search results for " Combination"

showing 10 items of 923 documents

Hepatitis C-related cirrhosis. Current status.

2016

Chronic hepatitis C virus (HCV) infection affects around 150 million people. It is a leading cause of liver related morbidity and mortality through its predisposition to liver fibrosis, cirrhosis and end-stage liver complications. New treatments based on direct-acting antivirals have opened a new era in the management of HCV cirrhosis. They allow for HCV eradication without substantial side effects in almost all cirrhotic patients, reducing the risk of hepatocellular carcinoma, liver decompensation and mortality. This review provides an update on HCV cirrhosis. The paper focuses on the disease burden and major progresses in the diagnosis, follow-up and treatment of this patient subgroup.

Liver Cirrhosismedicine.medical_specialtyCirrhosisLiver fibrosisGlobal HealthGastroenterologyAntiviral AgentsVirus03 medical and health sciences0302 clinical medicineChronic hepatitisInternal medicinemedicineHumansLiver decompensationDisease burdenbusiness.industryHepatitis CHepatitis C Chronicmedicine.diseaseCombined Modality Therapydigestive system diseasesLiver TransplantationSpain030220 oncology & carcinogenesisHepatocellular carcinoma030211 gastroenterology & hepatologyDrug Therapy CombinationbusinessMedicina clinica
researchProduct

Pegylated-interferon and ribavirin in liver transplant candidates and recipients with HCV cirrhosis: systematic review and meta-analysis of prospecti…

2008

SUMMARY Pegylated interferon with ribavirin (Peg/R) is the most effective therapy for chronic hepatitis C virus (HCV) but its utility and effectiveness after liver transplantation has been difficult to assess. We evaluated efficacy, tolerability, and safety of Peg/R in liver transplant candidates and recipients with HCV cirrhosis. We searched medical databases and conference proceedings between January 1999 and January 2008 selecting randomized and nonrandomized studies. Primary end points meta-analytically were: (1) sustained viral response (SVR) and (2) histological response. Secondary end points were: (1) treatment discontinuation, (2) mortality, and (3) rejection episodes. Pegylated int…

Liver Cirrhosismedicine.medical_specialtyCirrhosismedicine.medical_treatmentHepacivirusPharmacologyLiver transplantationAntiviral AgentsGastroenterologyPolyethylene Glycolschemistry.chemical_compoundPegylated interferonVirologyInternal medicineRibavirinmedicineHumansProspective StudiesRandomized Controlled Trials as TopicClinical Trials as Topiccirrhosis HCV pegylated interferon ribavirin transplantation.Hepatologybusiness.industryRibavirinvirus diseasesmedicine.diseaseHepatitis CLiver TransplantationDiscontinuationTransplantationRegimenTreatment OutcomeInfectious DiseaseschemistryTolerabilityDrug Therapy CombinationInterferonsbusinessmedicine.drug
researchProduct

[Hemostatic effectiveness of TachoSil® patches in radiofrequency assisted minor hepatic resection].

2011

Aim. Intra- and postoperative bleeding represents an extremely serious and frequent complication of hepatic surgery. The aim of this study was to evaluate the effectiveness of TachoSil (R) to improve hemostasis in radiofrequency assisted minor hepatic resection. Methods. Between July 2008 and June 2010, 31 patients underwent radiofrequency assisted minor hepatic resection. At the end of the liver resection a sponge of TachoSil (R) was applied on the liver. Results. The mean intraoperative bleeding from the liver was 56.1 mL (range 0-300 mL). No patients received intra- and postoperative blood transfusion. Surgical drains were removed between the first and the sixth-eight postoperative day. …

Liver neoplasms surgery; Haemostasis; Liver diseasesAdultAged 80 and overMaleSurgical SpongesHemostatic TechniquesLiver DiseasesThrombinFibrinogenLiver neoplasms surgeryMiddle AgedCombined Modality TherapySettore MED/18 - Chirurgia GeneraleDrug CombinationsHaemostasiCatheter AblationHepatectomyHumansFemaleAgedMinerva chirurgica
researchProduct

Anesthetic efficacy of Oraqix versus Hurricaine and placebo for pain control during non-surgical periodontal treatment

2014

Objectives: To evaluate the efficacy of Oraqix® during scaling and root planing (SRP) in comparison with 20% benzocaine and placebo. Study Design: 15 patients requiring 4 sessions of SRP were enrolled. For each patient, Oraqix®, Hurricaine®, vaseline or no anesthetic product were randomly assigned each to a quadrant. Treatment pain was evaluated on a 100 mm Visual Analog Scale (VAS) and on a Verbal Rating Scale (VRS). The amount of product administered, the need to re-anesthetise, patient and operator satisfaction and the onset of side-effects were also recorded. Results: Oraqix® was significantly better than nothing, with a reduction of VAS score to 13.3 units, but without significant diff…

Local anesthesiaMaleLidocaineBenzocaineRoot PlaningClinical trialsScaling and root planingPain treatmentAnesthesiaPeriodontologyAnesthetics LocalAnestèsia localMiddle Aged:CIENCIAS MÉDICAS [UNESCO]Ciencias de la saludBenzocaineTreatment OutcomeAnesthesiaUNESCO::CIENCIAS MÉDICASFemaleAnesthesia in dentistryPeriodontal diseasemedicine.drugAdultAnestèsia en odontologiamedicine.medical_specialtyVisual analogue scaleOdontologíaMalalties periodontalsPlaceboPrilocaineVaselineTractament del dolorDouble-Blind MethodmedicineHumansPain ManagementLidocaine Prilocaine Drug CombinationGeneral DentistryAgedbusiness.industryResearchLidocainePrilocaineSurgeryOtorhinolaryngologyAnestheticDental ScalingSurgerybusinessAssaigs clínicsMedicina Oral Patología Oral y Cirugia Bucal
researchProduct

Development of a long-lasting ventricular catheter impregnated with a combination of antibiotics.

2003

A ventricular silicone catheter impregnated with a combination of rifampin and a quinolone was developed in order to prevent ventricular shunt related infections. As model substance for the quinolones we used sparfloxacin, because of its specific physicochemical properties resulting in a quantitative detection also in the presence of a second antibiotic. In our study we focused especially on an optimization of the antibiotic release out of the impregnated catheters in order to develop long lasting devices with a broad antimicrobial spectrum. A release-optimized catheter was tested with an in vitro colonization test and additionally with a method developed to examine the spread of bacteria o…

Long lastingmedicine.medical_specialtyProsthesis-Related Infectionsmedicine.drug_classAntibioticsBiophysicsBioengineeringQuinolonesCerebral VentriclesBiomaterialschemistry.chemical_compoundSiliconeCatheters IndwellingDrug Delivery SystemsCoated Materials BiocompatibleStaphylococcus epidermidismedicineStaphylococcus epidermidisDrug Implantsbiologybusiness.industrySterilizationbiology.organism_classificationAntimicrobialQuinoloneSurgeryAnti-Bacterial AgentsEquipment Failure AnalysisCatheterSparfloxacinchemistryMechanics of MaterialsCeramics and CompositesEquipment ContaminationDrug Therapy CombinationRifampinbusinessmedicine.drugBiomaterials
researchProduct

Inhalation solutions — Which ones may be mixed? Physico-chemical compatibility of drug solutions in nebulizers — Update 2013

2014

AbstractMany patients suffering from chronic respiratory diseases rely on inhalation therapy with nebulizers. About 25% of patients who need to inhale several different drugs per day save time by mixing them for simultaneous inhalation. This review presents a comprehensive overview of the available data concerning physico-chemical compatibility of commonly mixed nebulizer solutions and suspensions. Information is based on our in vitro studies and a thorough literature search.Results indicate that many nebulizer solutions/suspensions are mixable without provoking incompatibilities. However, certain excipients contained in some of the tested drug products could be identified as a reason for i…

Lung DiseasesPulmonary and Respiratory MedicineDrugmedicine.medical_specialtymedia_common.quotation_subjectReviewCompatibilityAdministration InhalationmedicineMixtureHumansPediatrics Perinatology and Child HealthClinical efficacyIntensive care medicineAerosolmedia_commonInhalationbusiness.industryNebulizers and VaporizersDornase alfaAnti-Bacterial AgentsBronchodilator AgentsChemical compatibilityDrug CombinationsNebulizerNebulizer solution/suspensionAnesthesiaChronic DiseasePediatrics Perinatology and Child Healthbusinessmedicine.drugJournal of Cystic Fibrosis
researchProduct

Inhaled Surfactant in the treatment of accidental Talc Powder inhalation: a new case report

2011

Abstract The use of talcum powder is incorrectly part of the traditional care of infants. Its acute aspiration is a very dangerous condition in childhood. Although the use of baby powder has been discouraged from many authors and the reports of its accidental inhalation have been ever more rare, sometimes new cases with several fatalities have been reported. We report on a patient in which accidental inhalation of baby powder induced severe respiratory difficulties. We also point out the benefits of surfactant administration. Surfactant contributed to the rapid improvement of the medical and radiological condition, preventing severe early and late complications and avoiding invasive approac…

Lung Diseasesmedicine.medical_specialtymedicine.medical_treatmentTreatment outcomeCase Reportmacromolecular substancesTalcSettore MED/38 - Pediatria Generale E SpecialisticaPulmonary surfactantAdministration InhalationSurfactantmedicineHumansTalcum powderRespiratory physiotherapyIntensive care medicinePhospholipidsBiological ProductsInhalationRespiratory distressbusiness.industrylcsh:RJ1-570InfantRespiratory Physiotherapylcsh:PediatricsPulmonary SurfactantsBronchopulmonary LavageAccidental InhalationAnti-Bacterial AgentsBronchodilator AgentsRadiographyTreatment OutcomeCoughBaby powderTalcRespiratory DistressAccidentalDrug Therapy CombinationFemaleInhaled surfactant talc powder inhalationPowdersbusinessmedicine.drugItalian Journal of Pediatrics
researchProduct

The role of cMET in non-small cell lung cancer resistant to EGFR-Inhibitors: Did we really find the target?

2014

Abstract: The advent of the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) represented the most important innovation in NSCLC treatment over the last years. However, despite a great initial activity, secondary mutations in the same target, or different alterations in other molecular pathways, inevitably occur, leading to the emergence of acquired resistance, in median within the first year of treatment. In this scenario, the mesenchymal-epidermal transition (cMET) tyrosine kinase receptor and its natural ligand, the hepatocyte growth factor (HGF), seem to play an important role. Indeed either the overexpression or the amplification of cMET, as well as the overexpr…

Lung NeoplasmscMETcMET; cMET-Inhibitors; EGFR-TKIs resistance; HGF; NSCLC; Targeted therapies; Molecular Medicine; Pharmacology; Drug Discovery3003 Pharmaceutical Science; Clinical BiochemistryClinical BiochemistryAntineoplastic AgentsBiologyPharmacologyNSCLCReceptor tyrosine kinaseTargeted therapiesCarcinoma Non-Small-Cell LungDrug DiscoverymedicineHumansEpidermal growth factor receptorHGFLung cancerProtein Kinase InhibitorsEGFR inhibitorsEGFR-TKIs resistancePharmacologyClinical Trials as TopicPharmacology. TherapyDrug Discovery3003 Pharmaceutical ScienceAntibodies MonoclonalProto-Oncogene Proteins c-metmedicine.diseaseMolecular medicinerespiratory tract diseasesErbB ReceptorsDrug Resistance NeoplasmProto-Oncogene Proteins c-metbiology.proteinCancer researchMolecular MedicineDrug Therapy CombinationHepatocyte growth factorcMET-InhibitorTargeted therapiecMET-InhibitorsTyrosine kinasemedicine.drug
researchProduct

New Potential Therapeutic Approach for the Treatment of B-Cell Malignancies Using Chlorambucil/Hydroxychloroquine-Loaded Anti-CD20 Nanoparticles

2013

Current B-cell disorder treatments take advantage of dose-intensive chemotherapy regimens and immunotherapy via use of monoclonal antibodies. Unfortunately, they may lead to insufficient tumor distribution of therapeutic agents, and often cause adverse effects on patients. In this contribution, we propose a novel therapeutic approach in which relatively high doses of Hydroxychloroquine and Chlorambucil were loaded into biodegradable nanoparticles coated with an anti-CD20 antibody. We demonstrate their ability to effectively target and internalize in tumor B-cells. Moreover, these nanoparticles were able to kill not only p53 mutated/deleted lymphoma cell lines expressing a low amount of CD20…

Lymphomamedicine.medical_treatmentlcsh:MedicineApoptosisnanoparticles; Targeting strategies; LymphomaAggressive lymphomaMice SCIDPharmacologyAntibodies Monoclonal Murine-DerivedMiceDrug Delivery Systems0302 clinical medicineimmune system diseaseshemic and lymphatic diseasesNANOPARTICLESMedicinelcsh:ScienceCD200303 health sciencesMultidisciplinarybiologyNANOPARTICLES; ANTI-CD20; B-CELL MALIGNANCIESnanoparticleANTI-CD20Flow CytometryImmunohistochemistry3. Good healthDrug CombinationsLeukemia030220 oncology & carcinogenesisMonoclonalTargeting strategieFemaleRituximabRituximabHydroxychloroquineResearch Articlemedicine.drugLymphoma B-CellCell Survival03 medical and health sciencesMicroscopy Electron TransmissionAutophagyB-CELL MALIGNANCIESAnimalsTargeting strategies030304 developmental biologyChlorambucilbusiness.industrylcsh:RHydroxychloroquineImmunotherapyAntigens CD20medicine.diseaseDisease Models Animalbiology.proteinChlorambucillcsh:QbusinessPLoS ONE
researchProduct

Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR inhibitors: Rationale and importance to inhibiting these pathways in human health

2011

William H. Chappell 1 , Linda S. Steelman 1,2 , Jacquelyn M. Long 2 , Ruth C. Kempf 2 , Stephen L. Abrams 1 , Richard A. Franklin 1 , Jorg Basecke 3 , Franca Stivala 4 , Marco Donia 4 , Paolo Fagone 4 , Graziella Malaponte 4 , Maria C. Mazzarino 4 , Ferdinando Nicoletti 4 , Massimo Libra 4 , Danijela Maksimovic-Ivanic 5 , Sanja Mijatovic 5 , Giuseppe Montalto 6 , Melchiorre Cervello 7 , Piotr Laidler 8 , Michele Milella 9 , Agostino Tafuri 10 , Antonio Bonati 11 , Camilla Evangelisti 12 , Lucio Cocco 12 , Alberto M. Martelli 12,13 , and James A. McCubrey 1 1 Department of Microbiology and Immunology, Brody School of Medicine at East Carolina University 2 Department of Physics, Greenville, N…

MAPK/ERK pathwayAgingmedicine.medical_treatmentDrug ResistancerafPI3KTargeted therapycombination therapyPhosphatidylinositol 3-Kinases0302 clinical medicineTARGETED THERAPYCANCER STEM CELLSNeoplasmsCancer Stem CellsMedicineExtracellular Signal-Regulated MAP Kinases0303 health sciencesCombination TherapybiologyTOR Serine-Threonine KinasesMTORHuman health Ras inhibitors MEK ERKTargeted TherapyDiscovery and development of mTOR inhibitors3. Good healthDRUG RESISTANCECell Transformation NeoplasticOncology030220 oncology & carcinogenesismTORraf KinasesPremature agingMAP Kinase Signaling SystemReviewsSenescence03 medical and health sciencesCell Line TumorHumansPTENProtein kinase BPI3K/AKT/mTOR pathway030304 developmental biologyMitogen-Activated Protein Kinase Kinasesbusiness.industryAKTAktagingPTEN PhosphohydrolaseRafTransplantationSENESCENCEImmunologyras Proteinsbiology.proteinCancer researchaging; akt; cancer stem cells; combination therapy; drug resistance; mtor; pi3k; raf; senescence; targeted therapybusinessProto-Oncogene Proteins c-akt
researchProduct